Personalis, Inc. and Tempus AI, Inc. announced an expansion of their commercial relationship, with Tempus serving as the exclusive commercial diagnostic partner for Personalis’ ultra-sensitive tumor-informed minimal residual disease (MRD) platform. This collaboration aims to bring advanced MRD testing to market.
The companies launched their initial efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. This expanded partnership focuses on leveraging Tempus's extensive market reach to accelerate the adoption of Personalis's NeXT Personal MRD test.
This strategic move reinforces Tempus's commitment to providing cutting-edge diagnostic solutions. The exclusive nature of the partnership positions Tempus as a key player in the evolving MRD testing landscape for biopharmaceutical applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.